Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 734-740

  Puisset, Florent ^a,b   White Koning, Mélanie ^b   Kamar, Nassim ^c,d   Huart, Antoine ^c   Haberer, Frédérique ^b   Blasco, Hélène ^e   Le Guellec, Chantal ^e   Lafont, Thierry ^b   Grand, Anaïs ^a   Rostaing, Lionel ^c,d   Chatelut, Etienne ^b   Pourrat, Jacques ^c  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU RANGUEIL   (France)

^d CHU PURPAN   (France)

^e UNIVERSITÉ DE TOURS   (France)

Author keywords

Pharmacokinetics; Plasmapheresis; Rituximab

Indexed keywords

RITUXIMAB;

ADULT; ANTIBODY MEDIATED REJECTION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATIONAL STUDY; CRYOGLOBULINEMIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG ISOLATION; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; LUPUS VULGARIS; LYMPHOCYTE COUNT; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL;

PHARMACOKINETICS; PLASMAPHERESIS; RITUXIMAB;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PLASMAPHERESIS; TIME FACTORS;

EID: 84886932520     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12098     Document Type: Article

References (29)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
2. Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004; 30: 393-403. viii.
3. Tedeschi A, Vismara E, Ricci F, Morra E, Montillo M. The spectrum of use of rituximab in chronic lymphocytic leukemia. Onco Targets Ther 2010; 3: 227-246.
4. Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010; 70: 1445-1476.
5. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21: 49-56.
6. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004; 4: 398-402.
7. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318-326.
8. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008; 85: 1745-1754.
9. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
10. Fauvelle F, Petitjean O, Tod M, Guillevin L. Clinical pharmacokinetics during plasma exchange. Therapie 2000; 55: 269-275.
11. Okechukwu CN, Meier-Kriesche HU, Armstrong D, Campbell D, Gerbeau C, Kaplan B. Removal of basiliximab by plasmapheresis. Am J Kidney Dis 2001; 37: E11.
12. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58: 79-88.
13. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 2007; 27: 1529-1549.
14. Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, Le GC. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods 2007; 325: 127-139.
15. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195-222.
16. Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276-3284.
17. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
18. Tobinai K, Igarashi T, Itoh K, Kobayashi Y, Taniwaki M, Ogura M, Kinoshita T, Hotta T, Aikawa K, Tsushita K, Hiraoka A, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol 2004; 15: 821-830.
19. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
20. Cartron G, Blasco H, Paintaud G, Watier H, Le GC. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007; 62: 43-52.
21. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
22. Mangel J, Buckstein R, Imrie K, Spaner D, Franssen E, Pavlin P, Boudreau A, Pennell N, Combs D, Berinstein NL. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation. Ann Oncol 2003; 14: 758-765.
23. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125: 592-597.
24. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-1208.
25. Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 2005; 27: 785-792.
26. Iacona I, Lazzarino M, Avanzini MA, Rupolo M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000; 22: 295-301.
27. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007; 2: 932-937.
28. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
29. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010; 5: 2188-2198.